Kory James Wentworth Sells 11,388 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 11,388 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total transaction of $148,271.76. Following the sale, the chief financial officer owned 121,510 shares in the company, valued at approximately $1,582,060.20. This trade represents a 8.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Kory James Wentworth also recently made the following trade(s):

• On Monday, March 9th, Kory James Wentworth sold 5,089 shares of Entrada Therapeutics stock. The stock was sold at an average price of $13.00, for a total transaction of $66,157.00.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.25, for a total transaction of $97,853.00.

Entrada Therapeutics Stock Down 3.9%

TRDA opened at $12.98 on Friday. The business’s fifty day simple moving average is $11.28 and its 200 day simple moving average is $8.89. Entrada Therapeutics, Inc. has a 52 week low of $4.93 and a 52 week high of $13.65. The stock has a market cap of $496.87 million, a PE ratio of -3.75 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. As a group, equities analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TRDA. State of Wyoming raised its holdings in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after buying an additional 4,295 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the 2nd quarter worth $68,000. IHT Wealth Management LLC bought a new stake in Entrada Therapeutics in the 2nd quarter worth $72,000. Finally, AXQ Capital LP purchased a new position in shares of Entrada Therapeutics in the third quarter valued at about $67,000. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Oppenheimer began coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.